Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | HTR1F | P30939 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515604 | 0.72 | GRM4 (0.36) | CNR1 | |
| SCHEMBL16927762 | 0.72 | PDGFRA (0.37) | — | |
| SCHEMBL2931949 | 0.72 | GSK3B (0.40) | PARP1HTR1FHTR1AHDAC3HDAC1 | |
| SCHEMBL4225786 | 0.71 | PTGER1 (0.33) | PARP1 | |
| SCHEMBL10499583 | 0.71 | ELANE (0.44) | PARP1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4226046 | 0.71 | ELANE (0.31) | — | |
| Hydrochloric Acid SCHEMBL10395957 | 0.70 | ELANE (0.43) | PARP1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4215844 | 0.70 | ELANE (0.31) | — | |
| SCHEMBL10395836 | 0.69 | ELANE (0.49) | CYP2D6SYK | |
| SCHEMBL4228519 | 0.69 | ELANE (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | claimed |
| WO-2009013010-A2 | 5HT6-LIGANDS SUCH AS SULFONAMIDE DERIVATIVES IN DRUG- INDUCED WEIGHT-GAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | WO | claimed |
| EP-2018861-A1 | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-28 | — | — | EP | claimed |
| US-20090005417-A1 | Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-01-01 | — | — | US | claimed |
| EP-1869002-A1 | SUBSTITUTED INDAZOLYL SULFONAMIDE AND 2,3-DIHYDRO-INDOLYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-26 | — | — | EP | claimed |
| WO-2006069809-A1 | SUBSTITUTED INDAZOLYL SULFONAMIDE AND 2,3-DIHYDRO-INDOLYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | claimed |
| EP-1676841-A1 | Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments | Esteve Laboratorios Dr. Esteve S.A. (ES) | 2006-07-05 | — | — | EP | claimed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| EP-2081600-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-29 | — | — | EP | disclosed |
| EP-2040755-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-04-01 | — | — | EP | disclosed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | disclosed |
| WO-2009013010-A2 | 5HT6-LIGANDS SUCH AS SULFONAMIDE DERIVATIVES IN DRUG- INDUCED WEIGHT-GAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008034815-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-27 | — | — | WO | disclosed |
| EP-1902733-A1 | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | disclosed |
| EP-1869002-A1 | SUBSTITUTED INDAZOLYL SULFONAMIDE AND 2,3-DIHYDRO-INDOLYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006069809-A1 | SUBSTITUTED INDAZOLYL SULFONAMIDE AND 2,3-DIHYDRO-INDOLYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676841-A1 | Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments | Esteve Laboratorios Dr. Esteve S.A. (ES) | 2006-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | HTR6, HTR3B, HTR4 | PARP1 2150/4885HTR1F 16/4885HTR1A 8/4885 |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | PARP1 2059/4885HTR1F 34/4885HTR1A 20/4885 |
| US-20090005417-A1 | Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments | HTR6, TPH2, HTR5A | PARP1 4388/4885HTR1F 18/4885HTR1A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.